User:Tkadm30/Notebook/Endocannabinoids/Anandamide: Difference between revisions
From OpenWetWare
m (Yar moved page User:Etienne Robillard/Notebook/Endocannabinoids/Anandamide to User:Tkadm30/Notebook/Endocannabinoids/Anandamide: Automatically moved page while renaming the user "Etienne Robillard" to "[[User:Tkadm30|...) |
|||
(4 intermediate revisions by one other user not shown) | |||
Line 6: | Line 6: | ||
=== Notes === | === Notes === | ||
* The allosteric activation of PPAR-RXR heterodimer by anandamide (CB1/TRPV1 receptors) may facilitate hippocampal neurogenesis. | * The allosteric activation of PPAR-RXR heterodimer by anandamide (CB1/TRPV1 receptors) may facilitate hippocampal neurogenesis. (Reference needed) | ||
* Intracellular FABP5 expression may result in anandamide trafficking of heteromeric CB1 receptor. | * Intracellular FABP5 expression may result in anandamide trafficking of heteromeric CB1 receptor. (Reference needed) | ||
* Adenosine antagonism may potentiate retrograde trafficking of anandamide via heteromization of CB1 receptor. | * Adenosine antagonism (caffeine) may potentiate retrograde trafficking of anandamide via heteromization of CB1 receptor. (Reference needed) | ||
* Anandamide biosynthesis may | * Anandamide biosynthesis may enhance caffeine-induced diuresis. <cite>Paper3</cite> | ||
* Anandamide-oxytocin cross-talk (signal transduction) may modulate cellular stress response/vitamin D gene expression? | * Anandamide-oxytocin cross-talk (signal transduction) may modulate cellular stress response/vitamin D gene expression? | ||
Line 27: | Line 27: | ||
#Paper4 https://www.ncbi.nlm.nih.gov/pubmed/18832445 | #Paper4 https://www.ncbi.nlm.nih.gov/pubmed/18832445 | ||
//The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. | //The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. | ||
#Paper5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC20983/ | |||
//The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. | |||
</biblio> | </biblio> |
Latest revision as of 14:58, 2 October 2018
Intracellular anandamide trafficking as a promoter of neurogenesis acting through presynaptic CB1/FABP binding
The maturation and differentiation of neural stem cells via fatty-acid binding proteins (FABPs) signaling may require anandamide as a promoter of CB1-dependent neurogenesis. [1]
Hippocampal neurogenesis with synaptogenic promoter (DHA) is induced by intracellular and presynaptic CB1 receptor binding to anandamide. [2]
Notes
- The allosteric activation of PPAR-RXR heterodimer by anandamide (CB1/TRPV1 receptors) may facilitate hippocampal neurogenesis. (Reference needed)
- Intracellular FABP5 expression may result in anandamide trafficking of heteromeric CB1 receptor. (Reference needed)
- Adenosine antagonism (caffeine) may potentiate retrograde trafficking of anandamide via heteromization of CB1 receptor. (Reference needed)
- Anandamide biosynthesis may enhance caffeine-induced diuresis. [3]
- Anandamide-oxytocin cross-talk (signal transduction) may modulate cellular stress response/vitamin D gene expression?
See also
References
-
Type-1 (CB1) Cannabinoid Receptor Promotes Neuronal Differentiation and Maturation of Neural Stem Cells
-
Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide.
-
Diuretic Effects of Cannabinoids
-
The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway.
-
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.